|
MechanismSARS-CoV-2 S protein inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with IGY Life Sciences USA Inc
0 Patents (Medical) associated with IGY Life Sciences USA Inc
100 Deals associated with IGY Life Sciences USA Inc
100 Translational Medicine associated with IGY Life Sciences USA Inc